- Arrowhead Pharmaceuticals (NASDAQ:ARWR) has dosed the first patient in AROAPOC3-2001, a Phase 2b clinical study of ARO-APOC3, an investigational RNA interference (RNAi) therapeutic being developed as a treatment for patients with severe hypertriglyceridemia (SHTG).
- A total of ~300 participants will be enrolled in the study. Three dose levels of ARO-APOC3 (10 mg, 25 mg and 50 mg) will be evaluated against placebo in participants who have mean fasting triglycerides >=500 mg/dL (5.65 mmol/L).
- The primary objective of the study is to evaluate the safety and efficacy of ARO-APOC3 in adults with SHTG and to select a dosing regimen for later stage clinical studies in this patient population.
- The company also intends to initiate a Phase 2b study and a Phase 3 study of ARO-APOC3 in two additional patient populations in 2021.